Piper Sandler Initiates Coverage On Minimed Group with Neutral Rating, Announces Price Target of $16
Benzinga Newsdesk 7 months ago
NewsPrice TargetInitiationAnalyst Ratings
Piper Sandler analyst Matt O'Brien initiates coverage on Minimed Group (NASDAQ:MMED) with a Neutral rating and announces Price Target of $16.
Piper Sandler analyst Matt O'Brien initiates coverage on Minimed Group (NASDAQ:MMED) with a Neutral rating and announces Price Target of $16.